Morgan Stanley analyst Matthew Harrison downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Overweight to Equalweight with a price target of $21.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

Truist Securities Downgrades Fusion Pharmaceuticals (FUSN) to HoldMarch 19, 2024 11:45 AM William Blair Downgrades Fusion Pharmaceuticals (FUSN) to Market PerformMarch 19, 2024 10:47 AM Brookline Capital Markets Downgrades Fusion Pharmaceuticals (FUSN) to HoldMarch 19, 2024 10:28 AM Raymond James Downgrades Fusion Pharmaceuticals (FUSN) to Market PerformMarch 19, 2024 10:05 AM Jefferies Downgrades Fusion Pharmaceuticals (FUSN) to HoldMarch 19, 2024 10:00 AM Wedbush Downgrades Fusion Pharmaceuticals (FUSN) to NeutralMarch 19, 2024 8:52 AM Midday movers: Nvidia, Coinbase fall; Unilever risesMarch 19, 2024 8:08 AM Form DEFA14A Fusion Pharmaceuticals March 19, 2024 6:26 AM Form 8-K Fusion Pharmaceuticals For: Mar 18March 19, 2024 6:24 AM Leerink Partners Downgrades Fusion Pharmaceuticals (FUSN) to Market PerformMarch 19, 2024 6:03 AM Fusion Pharmaceuticals (FUSN) Acquired by AstraZeneca (AZN) for $21/sh Cash + $3 CVRMarch 19, 2024 4:13 AM Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat CancerMarch 19, 2024 3:00 AM